The behavior of therapeutic antibodies in immunotherapy

August 13, 2020

Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells. However, in the more than 20 years since their use began, the molecular mechanisms that underlie this therapy are still little understood. For the first time, scientists from the CNRS, Institut Pasteur and Université de Bordeaux have observed the interaction between therapeutic antibodies and their target protein. The research, published in Science on 14 August 2020, describes these molecular mechanisms and opens the way to the development of new treatments.

Non-Hodgkin lymphomas are among the most common cancers affecting almost 1.5 million people globally. They cause uncontrolled proliferation of B lymphocytes, a type of white blood cell, to the detriment of healthy cells. Since the end of the 1990s, immunotherapy had been a frontline treatment using synthetic antibodies to target a protein on the surface of B lymphocytes called CD20. The body's defences then identify these cells covered in antibodies as pathogens and destroy them.

Presently, the types of therapeutic antibodies used are classified into two groups according to how many CD20 molecules they bind to and the immunity response they trigger. Antibodies from the first group have the ability to interact with twice as many CD20 molecules than antibodies from the second group and can set off a cascading immune response called a "complement pathway". Until now, the molecular mechanisms at the root of underlying the differences between these two groups were unknown.

By using cryogenic electron microscopy, scientists from the CNRS, Institut Pasteur, and Université de Bordeaux1 were able, for the first time, to observe on an atomic level the interaction between the representatives of both groups of antibodies and their target molecules. They have shown that because of the availability of space, CD20 proteins can bind to two type 1 antibodies but to only one type 2 antibody. Due to their larger numbers on the surface of B lymphocytes, type 1 antibodies can form clusters. The team demonstrates that these clusters trigger the complement pathway which leads to the destruction of the target B lymphocytes. Type 2 antibodies, on the other hand, are thinly dispersed on the cell surface and therefore do not trigger a cascading response. Other independent immune responses are still able to destroy the cells.

Never before has the mechanism of action of therapeutic antibodies been described with such precision. This research could lead to new synthetic antibodies able to control a patient's immune response. In addition, this description of the mechanism activating the complement pathway opens the way to new research possibilities aiming at an understanding of how immune defences work.
-end-
Notes: 1- With scientists from the Laboratoire de Microbiologie Fondamentale et Pathogénicité (CNRS/Université de Bordeaux), the "Humoral Immunity" laboratory (Inserm/Institut Pasteur/Sorbonne Université), the "Mécanismes des protéines membranaires"

unit (Institut Pasteur) and the European Institute of Chemistry and Biology (IECB/Université de Bordeaux).

CNRS

Related Immune Response Articles from Brightsurf:

Boosting chickens' own immune response could curb disease
Broiler chicken producers the world over are all too familiar with coccidiosis, a parasite-borne intestinal disease that stalls growth and winnows flocks.

Cells sacrifice themselves to boost immune response to viruses
Whether flu or coronavirus, it can take several days for the body to ramp up an effective response to a viral infection.

Children's immune response more effective against COVID-19
Children and adults exhibit distinct immune system responses to infection by the virus that causes COVID-19, a finding that helps explain why COVID-19 outcomes tend to be much worse in adults, researchers from Yale and Albert Einstein College of Medicine report Sept.

Which immune response could cause a vaccine against COVID-19?
Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

Obesity may alter immune system response to COVID-19
Obesity may cause a hyperactive immune system response to COVID-19 infection that makes it difficult to fight off the virus, according to a new manuscript published in the Endocrine Society's journal, Endocrinology.

Immune response to Sars-Cov-2 following organ transplantation
Even patients with suppressed immune systems can achieve a strong immune response to Sars-Cov-2.

'Relaxed' T cells critical to immune response
Rice University researchers model the role of relaxation time as T cells bind to invaders or imposters, and how their ability to differentiate between the two triggers the body's immune system.

A novel mechanism that triggers a cellular immune response
Researchers at Baylor College of Medicine present comprehensive evidence that supports a novel trigger for a cell-mediated response and propose a mechanism for its action.

Platelets exacerbate immune response
Platelets not only play a key role in blood clotting, but can also significantly intensify inflammatory processes.

How to boost immune response to vaccines in older people
Identifying interventions that improve vaccine efficacy in older persons is vital to deliver healthy ageing for an ageing population.

Read More: Immune Response News and Immune Response Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.